Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mabwell-b (2493.HK)
Shanghai, SH, CN
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17. In addition, the company offers immunology products comprising 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial. Its bone disorder product pipeline consists of 1MW5011, an oral tablet for the treatment of osteoarthritis. Additionally, it provides ophthalmology products include 9MW0813, a recombinant VEGF receptor-antibody fusion protein for the treatment of ocular diseases related to vascularization; 9MW0211, a recombinant anti-VEGF humanized monoclonal antibody injection that is in Phase III clinical trials for the treatment of neovascularization-related eye diseases, such as neovascular age-related macular degeneration. Further, the company's hematology product comprises 9MW3011, a recombinant humanized anti-TMPRSS6 monoclonal antibody that is in Phase I clinical trials for the treatment of polycythemia vera and iron overload disorders, including beta-thalassemia. The company was founded in 2017 and is headquartered in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.80% | +9.61% | -3.54% | -5.57% | -5.57% | -5.57% | -5.57% | -5.57% | -5.57% | -5.57% | -5.57% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+231.6% ★ Q1'26: +184.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+6.9% Q1'26: +16.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-85.0% Q1'26: -216.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-130.7% Q1'26: -165.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-53.9% Q1'26: -50.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.3% ★ Q1'26: -0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.02× Q1'26: -3.42× (vs Q1'25)
| Metric |
Dec 2026 1 Rev. Ana. |
Dec 2027 2 Rev. Ana. |
|---|---|---|
| Revenue |
1.15B
1.07B – 1.24B
|
2.04B
1.80B – 2.27B
+76.6% YoY
|
| EBITDA |
-1.15B
-1.23B – -1.06B
|
-2.03B
-2.26B – -1.79B
-76.6% YoY
|
| EBIT |
-1.15B
-1.24B – -1.07B
|
-2.04B
-2.27B – -1.80B
-76.6% YoY
|
| Net Income |
—
— – —
|
—
— – —
|
| SGA |
3.71B
3.43B – 3.98B
|
6.55B
5.79B – 7.30B
+76.6% YoY
|
| EPS |
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-10 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-09 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hai Wu | Deputy GM, President of R&D and Director | 4M | — |
| Datao Liu | Chairman, CEO & GM | 3M | — |
| Huiguo Hu | Senior VP, CCO, Deputy GM, Secretary of the Board & Director | 2M | male |
| Xun Gui | VP, Deputy GM & Director | 2M | — |
| Xin Du | Chief Scientific Officer & President of Maiwei (US) | — | — |
| Chunshan Tang | Executive Director | — | male |
| Yinhan Guo | Chief Research & Development Officer | — | — |
| Jinchao Zhang | Deputy General Manager | — | male |
| Jun Hua | VP, CFO & Deputy GM | — | male |
| Shu Hai Wang | Deputy GM & Chief Medical Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2493.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
